Double-Blind, Randomized Trial of Docetaxel Plus Vandetanib Versus Docetaxel Plus Placebo in Platinum-Pretreated Metastatic Urothelial Cancer
Year: 2020
Type: article
Study design: Clinical Trial
Abstract: Vandetanib is an oral once-daily tyrosine kinase inhibitor with activity against vascular endothelial growth factor receptor 2 and epidermal growth factor receptor. Vandetanib in combination with docetaxel was assessed in patients with advanced urothelial cancer (UC) who progressed on prior platinum-based chemotherapy.
DOI: 10.17615/7hsf-zt65
Authors: Kantoff, Philip W., Sonpavde, Guru, Yu, Evan Y., Jacobus, Susanna, Kim, William Y., Morrissey, Stephanie C., Bubley, Glenn J., Petrylak, Daniel P., Mortazavi, Amir, Choueiri, Toni K., Ross, Robert W., Hutson, Thomas E., Buckle, Geoffrey C., Eisenberger, Mario A., Rosenberg, Jonathan E., Ryan, Christopher W., Quinn, David I., Vaishampayan, Ulka, Hahn, Noah M., Taplin, Mary-Ellen
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W4302031878